Of particular interest within this cohort are those patients for whom CA125 failed to provide an appropriate classification; i.e., cancer cases missed because of a low CA125 serum titre, and benign cases where elevated CA125 resulted in mis-classification and triage to a gynaecological oncologist. Here, MUC16 is linked to cancer.